Cancer Drug Discovery
Springer (Verlag)
978-94-024-0842-3 (ISBN)
Dr. Kyu-Won Kim College of Pharmacy, Seoul National University, Seoul, South Korea Dr. Jae Kyung Roh Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea Dr. Hee-Jun Wee College of Pharmacy, Seoul National University, Seoul, South KoreaDr. Chan Kim CHA Bundang Medical Center, CHA University, Seongnam-si, South Korea
Part Ⅰ. A Scientific Overview on Cancer.- 1. Advancements in Life Sciences and Characteristic Features of Cancer Cells.- 1.1 Characteristics of cancer cells.- 1.2 Characteristic interactions of cancer cells with neighboring cells and the tumor microenvironment.- 2. Advancement of the Science and History of Cancer and Anticancer Drugs.- Part Ⅱ. Cancer Drug Discovery – Types and History.- 3. Chronology of Anticancer Drug Development.- 3.1 A historical background of cancer chemotherapy.- 3.2 Development of the anticancer drug screening systems.- 3.3 Chronology of the anticancer drug development.- 3.4 Clinical application of anticancer drugs.- 4. Alkylating Anticancer Drugs.- 4.1 Classical alkylating drugs.- 4.2 Nonclassical alkylating drugs.- 4.3 Alkylating-like agents: platinum compounds.- 5. Antimetabolic Anticancer Drugs.- 5.1 Folic acid derivatives.- 5.2 Purine analogs.- 5.3 Pyrimidine analogs.- 6. Natural Product Anticancer Drugs.- 6.1 Plant-derived anticancer drugs.- 6.2 Anticancerantibiotics.- 7. Immunotherapeutic Anticancer Drugs and Other Miscellaneous Anticancer Drugs.- 7.1 Immunotherapeutic anticancer drugs.- 7.2 Other miscellaneous anticancer drugs.- 8. Hormonal Anticancer Drugs.- 8.1 Hormonal anti-prostate-cancer drugs.- 8.2 Hormonal anti-breast-cancer drugs.- 8.3 Other hormonal anticancer drugs.- 9. Molecular Targeted Anticancer Drugs.- 9.1 Tretinoin (all-trans retinoic acid, ATRA).- 9.2 Bcr-Abl Inhibitors.- 9.3 EGFR inhibitors.- 9.4 HER2 inhibitors.- 9.5 Angiogenesis inhibitors.- 9.6 Other kinase inhibitors.- 9.7 mTOR inhibitors.- 9.8 Other targeted anticancer antibody drugs.- 9.9 Epigenetic anticancer drugs.- 9.10 Proteasome inhibitors.- 9.11 Vismodegib: hedgehog pathway blocker.- 10. Complications of Anticancer Drugs and Their Management.- 10.1 Chemotherapy-induced nausea and vomiting (CINV).- 10.2 Myelotoxicity (bone marrow toxicity).- 10.3 Chemotherapy-induced diarrhea.- 10.4 Chemotherapy-induced constipation.- 10.5 Chemotherapy-induced urinary toxicity.- 10.6 Chemotherapy-induced pulmonary toxicity.- 10.7 Chemotherapy-induced neurotoxicity.- 10.8 Chemotherapy-induced neurotoxicity.- 10.9 Chemotherapy-induced oral mucositis.- 10.10 Anorexia.- 10.11 Tumor lysis syndrome.- 10.12 Extravasation of anticancer drugs.- 10.13 Chemotherapy-induced skin toxicity.- Part Ⅲ. A Paradigm Shift in Cancer Research.- 11. Advancements in Bioscience and New Cancer Drugs.- 11.1. Development of cancer drugs according to scientific advancements.- 11.2. New anticancer drugs.
Erscheinungsdatum | 10.09.2016 |
---|---|
Zusatzinfo | 134 Illustrations, color; 4 Illustrations, black and white; XVII, 276 p. 138 illus., 134 illus. in color. |
Verlagsort | Dordrecht |
Sprache | englisch |
Maße | 155 x 235 mm |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
Medizin / Pharmazie ► Pflege | |
Medizin / Pharmazie ► Pharmazie ► PTA / PKA | |
Studium ► Querschnittsbereiche ► Geschichte / Ethik der Medizin | |
ISBN-10 | 94-024-0842-8 / 9402408428 |
ISBN-13 | 978-94-024-0842-3 / 9789402408423 |
Zustand | Neuware |
Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
Haben Sie eine Frage zum Produkt? |
aus dem Bereich